Vimarsana
Biggest News Aggregation in the World

Page 7 - Michael Grey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Grey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Grey Today - Breaking & Trending Today

Peaky Blinders Season 6 Review: Cillian Murphy's Thomas Shelby comes 'full circle' in an epic series finale - Vimarsana News

Peaky Blinders Season 6 Review: Cillian Murphy's Thomas Shelby comes 'full circle' in an epic series finale

Peaky Blinders comes full circle for Cillian Murphy's Tommy Shelby in the finale. Read Pinkvilla's review below.

P&O Ferries debacle goes from bad to worse - Vimarsana News

P&O Ferries debacle goes from bad to worse

P&O Ferries bars ITF inspectors from welfare inspection at Dover after firing seven contract crew for drinking

'Peaky Blinders' Series Finale Will Be About Revenge, Says Director - Vimarsana News

'Peaky Blinders' Series Finale Will Be About Revenge, Says Director

'Peaky Blinders' director says that the final feature-length episode will revolve around the concept of revenge.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Sees Large Growth in Short Interest - Vimarsana News

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Sees Large Growth in Short Interest

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 748,800 shares, a growth of 55.7% from the February 28th total of 480,900 shares. Based on an average daily volume of 176,000 shares, the short-interest ratio is […]

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected to Post Earnings of -$1.30 Per Share - Vimarsana News

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected to Post Earnings of -$1.30 Per Share

Wall Street analysts forecast that Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) will report ($1.30) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Mirum Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.47) and the highest is ($1.03). Mirum Pharmaceuticals posted earnings of ($1.68) per share in the […]